Abstracts can be obtained from the ASH website.
Key Summaries and Submission Times:
Amgen Sponsored Abstracts
KYPROLIS® (carfilzomib)
Researcher-funded studies
BLINCYTO® (blinatumomab)
*E1910 is conducted through the National Cancer Institute (NCI), a component of the National Institutes of Health, and is conducted through the NCI-funded National Clinical Trials Network.
KYPROLIS® (carfilzomib)
BLINCYTO has received Breakthrough Therapy and Priority Review designations through the US Food and Drug Administration and is approved in the US for the treatment of:
In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of:
BLINCYTO® IMPORTANT SAFETY INFORMATION
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES
Warnings and Precautions
Undesirable effects
Dosage and Administration Guidelines
THE INDICATIONS
BiTE Technology Bispecific T Cell Interaction Generation (BiTE®)® is a targeted immuno-oncology platform designed to interact the patient’s own T cells with any specific tumor antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat other types of tumors with tumor-specific antigens. The BiTE platform aims to generate ready-to-use solutions, which have the possibility to make cutting-edge T-cell treatment available to all providers when their patients want it. Amgen provides more than a dozen BiTE molecules in a wide variety of hematologic malignancies and sham tumors, further investigating the generation of BiTE for patient enjoyment and prospective cure. To learn more about BiTE generation, scale at https //www. amgenoncology. com/bite-platform. html.
About KYPROLIS (carfilzomib) Proteasomes play a vital role in the function and expansion of mobiles by breaking down proteins that are broken down or no longer needed. 1 KYPROLIS has been shown to block proteasomes, causing excessive protein accumulation in mobiles. 2 In some mobiles, KYPROLIS® can cause mobile death, especially in mobiles with myeloma, because they are more likely to involve a higher amount of protein. 1,2
Since its first approval in 2012, more than 285,000 international patients have gained KYPROLIS. KYPROLIS is in the USA to:
KYPROLIS is also present in Algeria, Argentina, Australia, Bahrain, Belarus, Brazil, Canada, Chile, Colombia, Ecuador, Egypt, European Union, Hong Kong, India, Israel, Japan, Jordan, Kazakhstan, Kuwait, Lebanon, Macau and Malaysia. , Mexico, Morocco, New Zealand, Oman, Peru, Philippines, Qatar, Russia, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Switzerland, Taiwan, Thailand, Turkey and United Arab Emirates.
Cardiac toxicity
Acute renal failure
Tumor lysis syndrome
Pulmonary toxicity
Dyspnea
Hypertension
Venous thrombosis
Infusion-Related Reactions
Thrombocytopenia
Liver toxicity and liver failure.
Thrombotic microangiopathy
Posterior Reversible Encephalopathy Syndrome (PRES)
Increased Fatal and Severe Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Patients Who Are Not Candidates for Transplantation
Embryo-fetal toxicity
Undesirable effects
Please refer to the full prescription attached.
About AmgenAmgen is committed to unlocking the perspectives of biology for patients with serious diseases through the discovery, development, production, and delivery of cutting-edge human therapies. This technique begins by employing equipment such as complex human genetics to get to the bottom of the complexities of disease and perceive the basics of human biology.
Amgen focuses on spaces of meaningful and unfulfilled medical desires and leverages its expertise to seek answers that improve fitness outcomes and, in particular, people’s lives. A pioneer in biotechnology since 1980, Amgen has grown to become one of the world’s leading independent biotechnology companies, reaching millions of patients worldwide and emerging a line of drugs with disruptive potential.
Amgen is one of the 30 corporations that make up the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of “America’s Best Places to Work” by Newsweek, one of America’s “Climate Leaders” by USA Today, and one of the “World’s Best Companies” by TIME.
For more information, visit Amgen. com and follow us on X (formerly Twitter), LinkedIn, Instagram, TikTok, YouTube and Threads.
No forward-looking view can be guaranteed and actual effects would likely differ materially from those we anticipate. The discovery or identity of applicants for new products or the progression of new indications for existing products cannot be guaranteed and the transition from concept to product is uncertain; therefore, there can be no guarantee that any specific product candidate or progression of a new indication for an existing product will be successful and become an advertised product. Furthermore, preclinical effects do not guarantee safe and effective functionality of the product applicants in humans. The complexity of the human body cannot be modeled perfectly, or rarely even adequately, by computer systems, mobile culture, or animal models. The time it takes us to complete clinical trials and discharge regulatory approval to market a product has varied in the future and we anticipate similar variability in the future. Even when clinical trials are a success, the regulatory government would likely question the adequacy of approval of the endpoints we have selected. We expand product applicants internally and through licensing collaborations, partnerships and joint ventures. Applicants for products arising from relationships may be the subject of disputes between the parties or may not be as effective or as safe as we may have believed when entering into the relationship. Additionally, we or others may identify safety, appearance or production issues with our products when adding our devices after they are released to the market.
Our effects would likely be reflected through our ability to effectively advertise new and existing products locally and abroad, clinical and regulatory progressions involving existing and long-term products, expansion in sales of newly introduced products, festivals of other products, addition of biosimilars, tricks or delays in the production of our products. products and global economic situations. In addition, sales of our products are affected by pricing pressure, political and public scrutiny, and reimbursement policies imposed through third-party payers, including governments, personal insurance plans, and controlled care providers, and would potentially have effects through regulations, clinical and national regulatory progressions and updates. and foreign trends in managed care and containment of charges for physical care. In addition, our research, testing, pricing, marketing and other activities are subject to extensive regulation through domestic and foreign government regulators. Our business would possibly be affected through government investigations, litigation and product damage claims. In addition, our business may also be affected through the adoption of new tax legislation or exposure to new tax obligations. If we fail to meet the compliance obligations set forth in the Corporate Integrity Agreement between us and the U. S. Government, we could potentially be subject to significant sanctions. Furthermore, although we discharge patents for our products and technologies, the coverage granted through our patents and patent programs may be challenged, invalidated or circumvented by our competitors, or we may not be able to prevail in existing, long-term disputes over intellectual assets. . . We conduct a significant portion of our advertising production activities in a few key facilities, including Puerto Rico, and we also depend on third parties for a portion of our production activities, and sourcing restrictions would likely restrict sales of some of our products. and existing products. . candidate progression. An epidemic or similar public health threat, such as COVID-19, and public and government efforts to mitigate the spread of such disease, may also have an adverse effect on the sourcing of fabrics for our production, distribution operations. our products, marketing of our product applicants and our clinical trial operations, and any such occasion would likely have an adverse effect on the progression of our products, product sales, business and operational effects. We depend on collaborations with third parties for the advancement of some of our product applicants and for the marketing and sale of some of our advertising products. In addition, we compete with other corporations for many of our promoted products, as well as for the discovery and progression of new products. Additionally, certain raw materials, medical devices and parts of our products are supplied through exclusive third-party suppliers. Some of our distributors, consumers and payers have significant purchasing influence in their relationships with us. The discovery of significant disruptions with a product similar to one of our products and involving an entire range of products may also have an adverse effect on sales of the affected products and on our business and operations effects. Our efforts to collaborate with or obtain other corporations, products or technologies, and to integrate the operations of corporations or assist the products or technologies we have obtained, may not be successful. We cannot assure you that we will be able to realize any strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer than expected to materialize. We may not be able to integrate Horizon effectively, and any such acquisition or integration would likely take longer, be more complicated or charge more than anticipated. An outage, cyberattack or data security breach of our data generating systems may also compromise the confidentiality, integrity and availability of our systems and data. The value of our shares is volatile and may be affected at various times. Our business and operations could possibly be adversely affected by failure, or a belief of failure, in achieving our environmental, social and governance objectives. The effects of global climate change and resulting natural errors may also adversely affect our business and operations. Global economic situations could magnify certain risks affecting our industry. Our business functionality may also affect or restrict the ability of our board of directors to claim a dividend or our ability to pay a dividend or repurchase our regular inventory. We could not possibly access the capital and credit markets under conditions that are favorable to us, in any case.
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.
CONTACT: Amgen, Thousand OaksElissa Snook, 609-251-1407 (Media) Jessica Akopyan, 805-440-5721 (Media) Justin Claeys, 805-313-9775 (Investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-highlights-hematology-portfolio-at-ash-2023-302009588.html
SOURCE Amgen